ABT vs NVO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Abbott Laboratories exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative debt-to-equity ratio of 0.27. However, the stock is currently in a severe technical downtrend (0/100) and trades at a significant premium to its Graham Number ($50.12) and Intrinsic Value ($26.04). While analyst targets suggest significant upside to $131.44, the combination of bearish insider selling and poor short-term price performance offsets the strong balance sheet.
NVO presents a dichotomy between elite profitability and deteriorating growth. The Piotroski F-Score of 4/9 indicates stable but non-improving financial health, while the current price of $42.22 trades at a significant premium to both the Graham Number ($23.58) and Intrinsic Value ($25.27). Despite an exceptional ROE of 60.7% and strong margins, the company is facing negative YoY revenue (-7.6%) and earnings growth (-4.7%), resulting in a high PEG ratio of 4.53. The outlook is tempered by a bearish technical trend and liquidity concerns, though supported by a strong dividend profile and analyst 'Buy' ratings.
Compare Another Pair
Related Comparisons
ABT vs NVO: Head-to-Head Comparison
This page compares Abbott Laboratories (ABT) and Novo Nordisk A/S (NVO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.